7th Apr 2014 09:40
LONDON (Alliance News) - Oxford Biomedica PLC said Monday it had completed patient recruitment for its Phase I trial of neovascular wet age-related macular degeneration treatment RetinoStat.
The condition is age related, and causes blindness and visual impairment.
The company said that, based on pre-clinical data, RetinoStat may only require a single administration. The study will evaluate three dose levels to assess safety and biological activity in the eye. Results from the study are expected towards the end of 2014.
Shares in Oxford BioMedica were trading up 1.7% at 2.36 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica